Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.71 |
| ▸ | TGM2 | P21980 | 1/20 | 0.70 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.65 |
| ▸ | KRAS | P01116 | 5/20 | 0.64 |
| ▸ | RNASEL | Q05823 | 4/20 | 0.62 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.61 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.61 |
| ▸ | HINT1 | P49773 | 1/20 | 0.59 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29486374 | 1.00 | NT5E (0.71) | NT5ETGM2FUT5KRASRNASEL | |
| SCHEMBL29822597 | 1.00 | NT5E (0.71) | NT5ETGM2FUT5KRASRNASEL | |
| SCHEMBL29353975 | 1.00 | NT5E (0.71) | NT5ETGM2FUT5KRASRNASEL | |
| SCHEMBL31452129 | 0.99 | NT5E (0.72) | NT5ETGM2FUT5KRASRNASEL | |
| SCHEMBL18320601 | 0.96 | NT5E (0.72) | NT5ETGM2FUT5KRASRNASEL | |
| SCHEMBL21163271 | 0.94 | TGM2 (0.77) | NT5ETGM2FUT5KRASRNASEL | |
| SCHEMBL21163269 | 0.94 | TGM2 (0.77) | NT5ETGM2FUT5KRASRNASEL | |
| SCHEMBL22646974 | 0.94 | NT5E (0.67) | NT5ETGM2FUT5KRASRNASEL | |
| SCHEMBL20662559 | 0.94 | NT5E (0.67) | NT5ETGM2FUT5KRASRNASEL | |
| SCHEMBL21516016 | 0.94 | RNASEL (0.71) | TGM2RNASELP2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146251-A1 | DOUBLE STRANDED RNAi AGENTS, COMPOSITIONS AND METHODS OF USE | NOVARTIS AG (CH) | 2026-05-28 | — | — | US | disclosed |
| US-12611462-B2 | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof | CITY OF HOPE (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260015617-A1 | DOUBLE STRANDED RNAi AGENTS, COMPOSITIONS AND METHODS OF USE | NOVARTIS AG (CH) | 2026-01-15 | — | — | US | disclosed |
| WO-2025122871-A1 | MULTI-ARMED DENDRIMERIC OLIGONUCLEOTIDE NANOARCHITECTURES TO TARGET THE CYCLIC GMP-AMP (CGAS)/CYCLIC GMP-AMP RECEPTOR STIMULATOR OF INTERFERON GENES (STING) PATHWAY | NORTHWESTERN UNIVERSITY (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2024238321-A1 | COMPOSITIONS AND METHODS FOR TARGETED EPIGENETIC MODIFICATION | MAMMOTH BIOSCIENCES, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| CN-117751190-A | Compositions and methods for modulating SOS gene expression | 美国微哲默理有限责任公司 | 2024-03-22 | — | — | CN | disclosed |
| US-20220401563-A1 | COMPOUNDS AND COMPOSITIONS INCLUDING PHOSPHOROTHIOATED OLIGODEOXYNUCLEOTIDE, AND METHODS OF USE THEREOF | CITY OF HOPE | 2022-12-22 | — | — | US | disclosed |
| US-11464865-B2 | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof | CITY OF HOPE (US) | 2022-10-11 | — | — | US | disclosed |
| CN-114423284-A | T cell modulating polypeptides and methods of use thereof | 库尔生物制药有限公司 | 2022-04-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015617-A1 | DOUBLE STRANDED RNAi AGENTS, COMPOSITIONS AND METHODS OF USE | HMGCR, APOL1, LDLR | NT5E 948/4885TGM2 1696/4885FUT5 4204/4885 |
| US-11464865-B2 | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof | STAT3, STAT1, STAT4 | NT5E 2828/4885TGM2 3017/4885FUT5 3250/4885 |
| US-12611462-B2 | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof | STAT3, NSUN2, STAT1 | NT5E 3132/4885TGM2 3145/4885FUT5 4646/4885 |
| US-20260146251-A1 | DOUBLE STRANDED RNAi AGENTS, COMPOSITIONS AND METHODS OF USE | PCSK9, APOL1, PCSK7 | NT5E 469/4885TGM2 3981/4885FUT5 3831/4885 |
| US-20220401563-A1 | COMPOUNDS AND COMPOSITIONS INCLUDING PHOSPHOROTHIOATED OLIGODEOXYNUCLEOTIDE, AND METHODS OF USE THEREOF | STAT1, STAT3, STAT4 | NT5E 2877/4885TGM2 3111/4885FUT5 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.